指南导向药物治疗对新诊断外周动脉疾病患者5年死亡率的影响
该回顾性队列研究利用韩国全国医保索赔数据,纳入2006至2015年新诊断外周动脉疾病(PAD)且无明确心血管疾病的患者19,561例,评估指南导向药物治疗(GDMT)的普及率及5年全因死亡率。结果显示仅22.4%患者接受GDMT,GDMT组5年全因死亡率低于非GDMT组(2.8% vs 4.8%;调整后HR 0.329;95%CI 0.257-0.421;P<.001),且随指南推荐药物数量增加死亡率成比例下降。
要点
- 新诊断PAD患者中GDMT使用率仅22.4%,真实世界实践不足。
- GDMT组5年全因死亡率2.8%,非GDMT组4.8%(调整后HR 0.329;95%CI 0.257-0.421;P<.001)。
- 倾向匹配人群中GDMT组死亡率仍较低(HR 0.283;95%CI 0.217-0.370;P<.001)。
核心结论
- 新诊断PAD后,GDMT与较低的全因死亡率相关,且该关联不受已确诊心血管疾病影响。
- 该回顾性分析显示真实世界实践中PAD患者的GDMT使用率不足。
研究设计与样本
- 回顾性队列研究,使用韩国全国健康保险索赔数据,纳入2006至2015年新诊断PAD的患者。
- GDMT定义为PAD诊断后3个月内使用所有药物,包括抗血栓药、肾素-血管紧张素系统阻滞剂和他汀类。
- 研究共纳入19,561例新诊断PAD且无明确心血管疾病的患者。
- 主要终点为全因死亡率。
主要发现
- GDMT组4,378例(22.4%),非GDMT组15,183例(77.6%)。
- 5年随访期间,GDMT组全因死亡率2.8%,非GDMT组4.8%(调整后HR 0.329;95%CI 0.257-0.421;P<.001)。
- 倾向匹配人群中,GDMT组死亡率仍低于非GDMT组(HR 0.283;95%CI 0.217-0.370;P<.001)。
- 随着指南推荐药物数量的增加,死亡率成比例下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Current guidelines recommend that patients with peripheral artery disease (PAD) should be treated with antithrombotic agents, renin-angiotensin-system blockers, and statins. However, the clinical impact of guideline-directed medical therapy (GDMT) on long-term mortality in patients with newly diagnosed PAD remains unclear. We aimed to investigate the prevalence of GDMT and evaluate 5-year mortality according to GDMT after PAD diagnosis. METHODS: This retrospective cohort study, using nationwide health insurance claims data in Korea, included patients newly diagnosed with PAD between 2006 and 2015. GDMT was defined as the use of all drugs, including antithrombotic agents, renin-angiotensin-system blockers, and statins, within 3 months of PAD diagnosis. The primary endpoint was all-cause mortality. RESULTS: We investigated 19,561 newly diagnosed patients with PAD without proven cardiovascular disease. Among the study population, 4378 patients (22.4%) were categorized in the GDMT and 15,183 (77.6%) in the non-GDMT groups. During the 5-year follow-up, GDMT showed a lower incidence of all-cause mortality than that of non-GDMT (2.8% vs 4.8%; adjusted hazard ratio, 0.329; 95% confidence interval, 0.257-0.421; P < .001). Even in the propensity-matched population, GDMT showed a lower mortality rate than non-GDMT (hazard ratio, 0.283; 95% confidence interval, 0.217-0.370; P < .001). As the number of guideline-recommended drugs increased, the mortality rate decreased proportionately. CONCLUSIONS: After PAD diagnosis, GDMT was associated with a lower incidence of mortality regardless of proven cardiovascular disease. This retrospective analysis showed an insufficient prevalence of GDMT among patients with PAD in real-world practice.
引用
- Lee JH, Jeon HS, Lee JW, et al. Impact of guideline-directed medical therapy on 5-year mortality in patients with newly diagnosed peripheral artery disease. J Vasc Surg. 2023. PMID: 37597591. doi:10.1016/j.jvs.2023.08.103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。